Comparison
3 Methylglutaconic Aciduria Type 4 C1855126 vs 3q13 Microdeletion Syndrome C2931338
Clinical comparison between 3 Methylglutaconic Aciduria Type 4 and 3q13 Microdeletion Syndrome for differential diagnosis and treatment planning.
3 Methylglutaconic Aciduria Type 4 C1855126
A metabolic disorder affecting the nervous system that typically begins in childhood. Patients may experience movement difficulties, muscle stiffness, and developmental challenges. Care involves supportive therapies and symptom management.
3q13 Microdeletion Syndrome C2931338
A genetic disorder from missing material on chromosome 3q13, associated with developmental delays, intellectual disability, and various congenital features.
6 comparison axes
Onset
3 Methylglutaconic Aciduria Type 4 C1855126
0-null
3q13 Microdeletion Syndrome C2931338
Variable
Onset patterns differ
Severity
3 Methylglutaconic Aciduria Type 4 C1855126
severe
3q13 Microdeletion Syndrome C2931338
moderate
Different severity levels
Chronic
3 Methylglutaconic Aciduria Type 4 C1855126
Chronic
3q13 Microdeletion Syndrome C2931338
Chronic
Differing course
Communicable
3 Methylglutaconic Aciduria Type 4 C1855126
No
3q13 Microdeletion Syndrome C2931338
No
Different transmission
Body System
3 Methylglutaconic Aciduria Type 4 C1855126
metabolic
3q13 Microdeletion Syndrome C2931338
congenital
Same/different system
Category
3 Methylglutaconic Aciduria Type 4 C1855126
metabolic
3q13 Microdeletion Syndrome C2931338
genetic
Different category
Bottom line
3-methylglutaconic-aciduria-type-4-C1855126 and 3q13-microdeletion-syndrome-C2931338 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Methylglutaconic Aciduria Type 4 C1855126 | 3q13 Microdeletion Syndrome C2931338 | Discriminating power |
|---|---|---|---|
| Movement difficulty | May include childhood movement problems and muscle stiffness. | Not specifically established; developmental delay may affect motor skills. | Moderate |
| Developmental challenge | Developmental challenges may accompany a metabolic neurologic course. | Developmental delay and intellectual disability are described features. | Low |
| Congenital features | Not established from the supplied description. | Various congenital features may occur with the chromosomal deletion. | Moderate |
When to favor each condition
Choose 3 Methylglutaconic Aciduria Type 4 C1855126 when
Childhood neurologic symptoms with suspected metabolic disease
The description emphasizes nervous-system involvement and supportive metabolic care.
Moderate
Abnormal organic-acid findings needing diagnosis
The name suggests a metabolic aciduria, but a result alone is not diagnostic.
Moderate
Severe course without a known chromosomal deletion
Severity is listed as severe, though exact course is not established.
Low
Choose 3q13 Microdeletion Syndrome C2931338 when
Developmental delay with suspected chromosomal cause
The condition is defined by missing chromosome 3q13 material.
High
Congenital features plus intellectual disability
These are the principal features in the supplied description.
Moderate
Moderate congenital presentation without metabolic evidence
It is categorized as congenital and genetic rather than metabolic.
Moderate
How key tests differ
| Test | 3 Methylglutaconic Aciduria Type 4 C1855126 | 3q13 Microdeletion Syndrome C2931338 | Interpretation |
|---|---|---|---|
| Urine organic acids | May show 3-methylglutaconic acid elevation, but cutoffs are not supplied. | No characteristic organic-acid pattern is established. | An abnormal result supports metabolic evaluation but does not alone confirm type 4. |
| Chromosomal microarray | No 3q13 deletion is implied by the supplied data. | May identify missing material at chromosome 3q13. | A confirmed deletion supports the syndrome; clinical correlation remains necessary. |
| Neurologic assessment | May document movement difficulty, stiffness, and developmental effects. | May document developmental delay and intellectual disability. | Findings overlap and cannot reliably distinguish the conditions alone. |
Prognosis comparison
3 Methylglutaconic Aciduria Type 4 C1855126
- Outcome
- Potentially severe chronic neurologic course; exact outcomes are not established.
- Factors
- Symptom severity, developmental impact, and response to supportive care.
3q13 Microdeletion Syndrome C2931338
- Outcome
- Generally described as moderate and chronic, with variable individual effects.
- Factors
- Extent of deletion, congenital features, and developmental or intellectual needs.
Time frame: Often recognized in childhood, but onset and long-term course vary.
Available evidence does not establish mortality, prevalence, or a uniform prognosis.
Complications comparison
| Complication | Presentation |
|---|---|
| Neurologic impairment | Movement difficulty and muscle stiffness may occur. Motor effects are not specifically established. Severity and permanence are not quantified in the source. |
| Developmental disability | Developmental challenges may occur. Developmental delay and intellectual disability are described. The degree varies and requires individual assessment. |
| Congenital anomalies | Not established here. Various congenital features may be present. Specific anomalies and their frequency are not supplied. |
Patient education highlights
- HighDiagnosis
Neither a test abnormality nor developmental delay alone proves either diagnosis; specialist review is needed.
- HighCare
Care is generally supportive and individualized; no treatment dose or protocol is established here.
- MediumInheritance and cause
One condition is metabolic and the other chromosomal; families should discuss testing and counseling with clinicians.